{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T06:40:27Z","timestamp":1724654427991},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,25]]},"DOI":"10.7759\/cureus.67772","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:52:03Z","timestamp":1724651523000},"source":"Crossref","is-referenced-by-count":0,"title":["Morphology, Morphometry, and Immunohistochemical Profile of Megakaryocytes and Bone Marrow Microenvironment in Disease Progression and Therapy Resistance in Chronic Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Sreerag","family":"Kana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debdatta","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhee","family":"Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Nachiappa Ganesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harichandrakumar","family":"KT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14319\/ijcto.0302.2","article-title":"Imatinib resistance mutation analysis: experience from a tertiary oncology center","volume":"3","author":"Suresh Babu M","year":"2015","unstructured":"Suresh Babu M, Sirsath N, Lakshmaiah K, et al.. Imatinib resistance mutation analysis: experience from a tertiary oncology center. Int J Cancer Ther Oncol. 2015, 3:03022. 10.14319\/ijcto.0302.2","journal-title":"Int J Cancer Ther Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien SG","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, et al.. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348:994-1004. 10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves R","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel). 2021, 13:4820. 10.3390\/cancers13194820","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4137\/BMI.S22438","article-title":"Efficacy of dasatinib in a CML patient in blast crisis with F317L mutation: a case report and literature review","volume":"10","author":"Morozova EV","year":"2015","unstructured":"Morozova EV, Vlasova YY, Pryanishnikova MV, Lepik KV, Afanasyev BV. Efficacy of dasatinib in a CML patient in blast crisis with F317L mutation: a case report and literature review. Biomark Insights. 2015, 10:43-7. 10.4137\/BMI.S22438","journal-title":"Biomark Insights"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/jbio.200910072","article-title":"In vivo imaging of hematopoietic stem cells and their microenvironment","volume":"2","author":"Lo Celso C","year":"2009","unstructured":"Lo Celso C, Wu JW, Lin CP. In vivo imaging of hematopoietic stem cells and their microenvironment. J Biophotonics. 2009, 2:619-31. 10.1002\/jbio.200910072","journal-title":"J Biophotonics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.8.2293","article-title":"Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches","volume":"97","author":"Nilsson SK","year":"2001","unstructured":"Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood. 2001, 97:2293-9. 10.1182\/blood.v97.8.2293","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3707","article-title":"Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion","volume":"20","author":"Bruns I","year":"2014","unstructured":"Bruns I, Lucas D, Pinho S, et al.. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014, 20:1315-20. 10.1038\/nm.3707","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3706","article-title":"Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells","volume":"20","author":"Zhao M","year":"2014","unstructured":"Zhao M, Perry JM, Marshall H, et al.. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med. 2014, 20:1321-6. 10.1038\/nm.3706","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.10.095","article-title":"Megakaryocytes are essential for HSC quiescence through the production of thrombopoietin","volume":"454","author":"Nakamura-Ishizu A","year":"2014","unstructured":"Nakamura-Ishizu A, Takubo K, Fujioka M, Suda T. Megakaryocytes are essential for HSC quiescence through the production of thrombopoietin. Biochem Biophys Res Commun. 2014, 454:353-7. 10.1016\/j.bbrc.2014.10.095","journal-title":"Biochem Biophys Res Commun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906698","article-title":"Megakaryocytes are regulators of the tumor microenvironment and malignant hematopoietic progenitor cells in myelofibrosis","volume":"12","author":"Varricchio L","year":"2022","unstructured":"Varricchio L, Hoffman R. Megakaryocytes are regulators of the tumor microenvironment and malignant hematopoietic progenitor cells in myelofibrosis. Front Oncol. 2022, 12:906698. 10.3389\/fonc.2022.906698","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2004.020610","article-title":"Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol","volume":"59","author":"Naresh KN","year":"2006","unstructured":"Naresh KN, Lampert I, Hasserjian R, et al.. Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol. J Clin Pathol. 2006, 59:903-11. 10.1136\/jcp.2004.020610","journal-title":"J Clin Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25527","article-title":"Monitoring molecular response in chronic myeloid leukemia","volume":"117","author":"Cortes J","year":"2011","unstructured":"Cortes J, Quint\u00e1s-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011, 117:1113-22. 10.1002\/cncr.25527","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow PJ","year":"1977","unstructured":"Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage. Am J Med. 1977, 63:125-30. 10.1016\/0002-9343(77)90124-3","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.1.158.158","article-title":"Evidence for a multistep pathogenesis of chronic myelogenous leukemia","volume":"58","author":"Fialkow PJ","year":"1981","unstructured":"Fialkow PJ, Martin PJ, Najfeld V, et al.. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 1981, 58:158-63. 10.1182\/blood.V58.1.158.158","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi A","year":"2008","unstructured":"Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008, 22:14-22. 10.1038\/sj.leu.2404955","journal-title":"Leukemia"},{"key":"ref17","article-title":"Megakaryocytes in chronic phase of chronic myeloid leukemia: a descriptive case series","volume":"3","author":"Arunachalam AK","year":"2016","unstructured":"Arunachalam AK, Jain M, Kumar A, et al.. Megakaryocytes in chronic phase of chronic myeloid leukemia: a descriptive case series. Ann Pathol Lab Med. 2016, 3:176-82.","journal-title":"Ann Pathol Lab Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0300-2977(97)00018-1","article-title":"Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia","volume":"51","author":"Michiels JJ","year":"1997","unstructured":"Michiels JJ. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Neth J Med. 1997, 51:57-64. 10.1016\/s0300-2977(97)00018-1","journal-title":"Neth J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s002920050073","article-title":"Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases (Article in German)","volume":"16","author":"Nafe R","year":"1995","unstructured":"Nafe R, Holgado de Colombo S, Choritz H, Georgii A. Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases (Article in German). Pathologe. 1995, 16:34-40. 10.1007\/s002920050073","journal-title":"Pathologe"},{"key":"ref20","article-title":"Megakaryocyte morphometry in chronic myeloid leukemia and thrombocytopenic purpura","volume":"16","author":"Tatapudi SV","year":"2005","unstructured":"Tatapudi SV, Basu D. Megakaryocyte morphometry in chronic myeloid leukemia and thrombocytopenic purpura. Biomed Res. 2005, 16:93-6.","journal-title":"Biomed Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2021.1744","article-title":"CD44: a potential therapeutic target in chronic myeloid leukemia","volume":"76","author":"Shi R","year":"2021","unstructured":"Shi R, Liu X. CD44: a potential therapeutic target in chronic myeloid leukemia. Pharmazie. 2021, 76:574-8. 10.1691\/ph.2021.1744","journal-title":"Pharmazie"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Grosso S","year":"2009","unstructured":"Grosso S, Puissant A, Dufies M, et al.. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther. 2009, 8:1924-33. 10.1158\/1535-7163.MCT-09-0168","journal-title":"Mol Cancer Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/286671-morphology-morphometry-and-immunohistochemical-profile-of-megakaryocytes-and-bone-marrow-microenvironment-in-disease-progression-and-therapy-resistance-in-chronic-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:52:08Z","timestamp":1724651528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/286671-morphology-morphometry-and-immunohistochemical-profile-of-megakaryocytes-and-bone-marrow-microenvironment-in-disease-progression-and-therapy-resistance-in-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,25]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.67772","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,25]]}}}